Evaluation of BI 3731579 Tolerability Across Multiple Dosages in Healthy Volunteers

The primary objective of this study is to evaluate the **tolerability** of different doses of BI 3731579 in healthy individuals. Understanding the tolerability of this compound is clinically relevant as it provides foundational safety data necessary for the development of potential therapeutic applications. This study is conducted with healthy volunteers to ensure that the observed effects are attributable to the compound itself, without interference from underlying health conditions.

The clinical trial involves **healthy volunteers** as the study population, with both male and female participants included. The age range of participants is categorized as adults, specifically between 18 to 65 years. The trial does not focus on a vulnerable population, and the sponsor has not provided information regarding the total number of participants. Participants were selected based on their general health status, ensuring they are free from any significant medical conditions. Lifestyle considerations such as diet, physical activity, and habits were not specified in the available data. The sponsor did not provide detailed inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the **tolerability** of varying doses of BI 3731579 in healthy individuals. This study is categorized as a Phase 3 trial and is expected to commence recruitment on December 17, 2024, with an estimated completion date of May 1, 2025. The trial will employ a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be randomly assigned to receive different doses of the investigational product or a placebo, with neither the participants nor the investigators aware of the group assignments, thus maintaining the double-blind nature of the study.

The sequence of study visits will begin with an inclusion visit, also known as the screening visit, where potential participants will be assessed for eligibility based on predefined criteria. Following successful screening, participants will be enrolled in the study and will attend a series of follow-up visits at specified intervals to monitor their response to the treatment and to collect data on safety and tolerability. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the outcomes of the trial.

The expected duration of participant involvement will span the entire trial period, from the initial screening to the end-of-study visit. However, certain conditions may necessitate early termination from the study, such as adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is structured to ensure the safety and well-being of participants while providing valuable insights into the effects of BI 3731579 in a healthy population.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on December 17, 2024, with an estimated completion date of May 1, 2025. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for these assessments, are not specified in the provided information. The trial's focus on efficacy is aligned with the objectives typical of a Phase 3 study, which generally aims to confirm the effectiveness of a treatment in a larger patient population. The trial's design and execution will adhere to rigorous standards to ensure the reliability and validity of the efficacy data collected.